4月27日，据CDE官网消息，山东京卫制药有限公司联合申请药品“米诺地尔泡沫剂（男用）”，获得临床试验默示许可，受理号CYHL2500041。
公示信息显示，药品“米诺地尔泡沫剂（男用）”适应症：本品是一种含有5%米诺地尔的白色泡沫，仅用于头皮，有助于男性头发再生。
山东京卫制药有限公司，成立于1993年，位于泰安市，是一家以从事医药制造业为主的企业。企业注册资本11885.05098万人民币，实缴资本11885.05098万人民币。
通过天眼查大数据分析，山东京卫制药有限公司共对外投资了2家企业，参与招投标项目1749次，知识产权方面有商标信息146条，专利信息129条，此外企业还拥有行政许可182个。
主要股东信息显示，山东京卫制药有限公司由李铁军持股36.0313%、扈斌持股11.9491%、泰安丰衍投资管理合伙企业（有限合伙）持股7.3719%、泰安天木投资管理合伙企业（有限合伙）持股7.3302%、张红英持股6.7986%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.